Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17727702 | 1.00 | TLR4 (0.38) | TLR4TP53GAAACLYTRPV1 | |
| SCHEMBL4145794 | 1.00 | TLR4 (0.38) | TLR4TP53GAAACLYTRPV1 | |
| SCHEMBL15093757 | 0.91 | TLR4 (0.37) | TLR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4146514 | 0.91 | TLR4 (0.49) | TLR4TP53GAAACLYNPC1 | |
| SCHEMBL4163042 | 0.91 | TLR4 (0.37) | TLR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14136690 | 0.91 | TLR4 (0.49) | TLR4TP53GAAACLYNPC1 | |
| SCHEMBL14136752 | 0.91 | TLR4 (0.37) | TLR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4141115 | 0.91 | TLR4 (0.49) | TLR4TP53GAAACLYNPC1 | |
| SCHEMBL17727727 | 0.91 | TLR4 (0.49) | TLR4TP53GAAACLYNPC1 | |
| SCHEMBL4146713 | 0.91 | TLR4 (0.41) | TLR4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935879-B1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | CD40, LITAF, TNF | TLR4 29/4885TP53 3239/4885GAA 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.